Phenytoin

Phenytoin (5,5-Diphenylhydantoin) is a potent Voltage-gated Na+ channels (VGSCs) blocker. Phenytoin has antiepileptic activity and reduces breast tumour growth and metastasis in mice[1][2].

Product Specifications

CAS Number

[57-41-0]

Product Name Alternative

5,5-Diphenylhydantoin

UNSPSC

12352005

Hazard Statement

H302, H351, H360

Target

Sodium Channel; Virus Protease

Type

Reference compound

Related Pathways

Anti-infection; Membrane Transporter/Ion Channel

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/phenytoin.html

Purity

99.95

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C1NC(C(C2=CC=CC=C2)(C3=CC=CC=C3)N1)=O

Molecular Formula

C15H12N2O2

Molecular Weight

252.27

Precautions

H302, H351, H360

References & Citations

[1]Rogawski, M.A. and W. Loscher, The neurobiology of antiepileptic drugs. Nat Rev Neurosci, 2004. 5 (7) : p. 553-64.|[2]Porter, R.J., et al., Mechanisms of action of antiseizure drugs. Handb Clin Neurol, 2012. 108: p. 663-81.|[3]Balaji, S., Medical therapy for sudden death. Pediatr Clin North Am, 2004. 51 (5) : p. 1379-87.|[4]Michaela Nelson, et al. The sodium channel-blocking antiepileptic drug phenytoin inhibits breast tumour growth and metastasis. Mol Cancer. 2015 Jan 27;14 (1) :13.|[5]Assaggaf MA, et al. Prevention of phenytoin-induced gingival overgrowth by lovastatin in mice. Am J Pathol. 2015 Jun;185 (6) :1588-99.

Shipping Conditions

Room Temperature

Storage Conditions

-20°C, 3 years; 4°C, 2 years (Powder)

Scientific Category

Reference compound1

Clinical Information

Launched

Citation 01

Cell Rep Methods. 2023 Oct 23;3 (10) :100599.|Oxid Med Cell Longev. 2022 Mar 28;2022:8538296.|Regen Ther. 2023 Jul 6:24:201-210.|Int Immunopharmacol. 2023 Feb:115:109706.|University of Glasgow. School of Cancer Sciences.